Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kenporen Member Societies Report Surplus 3 Years in a Row in FY2005
August 21, 2006
- New Antibody Manufacturing Technology Established: Chiome Bioscience
August 21, 2006
- Korosho to Review Its Gastric Cancer Detection Program
August 21, 2006
- SymBio Initiates PI Clinical Trial of Bendamustine
August 21, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 21, 2006
- Actual R&D Tax Reduction Rate Was Only 7.3% in FY2005: JPMA
August 21, 2006
- DSP to Place Top Priority on Domestic Infrastructure in Mid-Term Plan
August 21, 2006
- SEMIANR Micardis Improves Insulin-Resistant Hypertension
August 21, 2006
- JMIRI to Launch Prescription Data Analysis Service
August 21, 2006
- R&D NEWS IN BRIEF
August 21, 2006
- BUSINESS NEWS IN BRIEF ～1～
August 21, 2006
- BUSINESS NEWS IN BRIEF ～2～
August 21, 2006
- SEMINAR "India-Japan Bio-Pharma Partnership Summit" to Be Held in Tokyo
August 21, 2006
- Wholesalers Have Not Yet Offered Rock-Bottom Prices: NPhA
August 7, 2006
- 28 Hospitals Participating in Shizuoka Clin. Trial Network
August 7, 2006
- Price Agreement Rate Exceeded 50% in 1st Qtr: Suzuken
August 7, 2006
- R&D NEWS IN BRIEF
August 7, 2006
- Nippon Chemiphar Aims for \10 Bil. in GE Drug Sales in FY2006
August 7, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 7, 2006
- Rate of Generic Drug Substitution Still Low: ASTEM
August 7, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…